Variables
|
Number
|
Median survival time (month)
|
95% confidence interval (CI)
|
χ2
|
P-value
|
---|
Race
| | | | | |
White
|
2255
|
44
|
41.617–46.383
|
35.071
|
< 0.001
|
Black
|
462
|
31
|
27.607–34.393
| | |
Other
|
200
|
43
|
31.973–54.027
| | |
Grade
| | | | | |
1
|
287
|
46
|
37.721–54.279
| | |
2
|
1440
|
46
|
42.998–49.002
|
45.128
|
< 0.001
|
3–4
|
1190
|
34
|
31.198–37.002
| | |
Marital
| | | | | |
Married
|
1416
|
48
|
44.517–51.483
|
45.771
|
< 0.001
|
Unmarried
|
1501
|
36
|
33.209–38.791
| | |
Age
| | | | | |
≤ 35
|
134
|
56
|
38.548–73.452
| | |
35 < age < 60
|
1345
|
46
|
42.387–49.613
|
70.468
|
< 0.001
|
≥ 60
|
1438
|
36
|
33.066–38.934
| | |
Ethnic origin
| | | | | |
Spanish-Hispanic-Latino
|
289
|
47
|
41.597–52.403
|
2.103
|
0.147
|
Non-Spanish-Hispanic-Latino
|
2628
|
41
|
38.983–43.017
| | |
Laterality
| | | | | |
Left
|
1525
|
42
|
39.446–44.554
|
0.017
|
0.896
|
Right
|
1392
|
42
|
39.085–44.915
| | |
Histology
| | | | | |
IDC
|
2351
|
44
|
41.537–46.463
|
25.295
|
< 0.001
|
Non-IDC
|
566
|
36
|
32.245–39.755
| | |
T stage
| | | | | |
T1
|
383
|
47
|
38.824–55.176
| | |
T2
|
1158
|
47
|
42.855–51.145
|
53.468
|
< 0.001
|
T3
|
553
|
40
|
35.692–44.308
| | |
T4
|
823
|
34
|
30.984–37.016
| | |
N stage
| | | | | |
N0
|
704
|
39
|
34.668–43.332
| | |
N1
|
1326
|
43
|
39.941–46.059
|
5.582
|
0.134
|
N2
|
406
|
43
|
37.639–48.361
| | |
N3
|
481
|
42
|
38.004–45.996
| | |
Radiation
| | | | | |
Yes
|
1302
|
46
|
42.593–49.407
|
14.906
|
< 0.001
|
No
|
1615
|
39
|
36.512–41.488
| | |
Chemotherapy
| | | | | |
Yes
|
1564
|
48
|
44.242–51.758
|
64.579
|
< 0.001
|
No
|
1353
|
36
|
33.254–38.746
| | |
Subtype
| | | | | |
ER + /HER2−
|
2114
|
43
|
41.030–44.970
| | |
ER + /HER2 +
|
433
|
57
|
48.725–65.275
|
242.199
|
< 0.001
|
HER2 +
|
122
|
73
|
0
| | |
TNBC
|
248
|
13
|
11.349–14.651
| | |
ER
| | | | | |
Positive
|
2532
|
44
|
42.077–45.923
|
91.338
|
< 0.001
|
Negative
|
385
|
18
|
14.319–21.681
| | |
PR
| | | | | |
Positive
|
2121
|
46
|
43.765–48.235
|
97.923
|
< 0.001
|
Negative
|
796
|
27
|
23.973–30.027
| | |
HER2
| | | | | |
Positive
|
555
|
58
|
46.618–69.382
|
30.843
|
< 0.001
|
Negative
|
2362
|
40
|
37.931–42.069
| | |
Primary surgery
| | | | | |
Operation
|
1245
|
56
|
51.508–60.492
|
146.023
|
< 0.001
|
Non-operation
|
1672
|
33
|
30.830–35.170
| | |
Surgical mode
| | | | | |
Non-operation
|
1672
|
33
|
30.830–35.170
| | |
BCS
|
381
|
70
|
0
|
157.117
|
< 0.001
|
Mastectomy
|
255
|
59
|
45.751–72.249
| | |
Radical mastectomy
|
609
|
48
|
43.369–52.631
| | |
- ER estrogen receptor, PR progesterone receptor, Her-2 human epidermal growth factor receptor 2, IDC infiltrating ductal carcinoma, BCS breast conserving surgery, TNBC triple-negative breast cancer